Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Pazoren is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Pazoren is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The efficacy of Pazoren for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended starting dose of Pazopanib is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). The dose of Pazopanib should not exceed 800 mg. Tablets should not be crushed due to the potential for increased rate of absorption which may affect systemic exposure. If a dose is missed, it should not be taken if it is less than 12 hours until the next dose. Or, as directed by the registered physicians.
Side Effects
Common side effects of Pazoren include: Hepatic Toxicity and Hepatic Impairment QT Prolongation and Torsades de Pointes Cardiac Dysfunction Hemorrhagic Events Arterial and Venous Thromboembolic Events Thrombotic Microangiopathy Gastrointestinal Perforation and Fistula Interstitial Lung Disease/Pneumonitis Reversible Posterior Leukoencephalopathy Syndrome Hypertension Hypothyroidism Proteinuria Tumor Lysis Syndrome Infection Increased Toxicity with Other Cancer Therapy
Cautions & Contraindications
Warnings & Precautions
Hepatic Toxicity and Hepatic Impairment: In clinical trials with Pazoren, hepatotoxicity, manifested as increases in serum transaminases (alanine transferase [ALT], aspartate aminotransferase [AST]) and bilirubin, was observed. This hepatotoxicity can be severe and fatal. Patients older than 65 years are at greater risk for hepatotoxicity. Transaminase elevations occur early in the course of treatment (92.5% of all transaminase elevations of any grade occurred in the first 18 weeks).QT Prolongation and Torsades De Pointes: In the RCC trials of Pazoren, QT prolongation (greater than or equal to 500 msec) was identified on routine electrocardiogram (ECG) monitoring in 2% (11/558) of patients. Torsades de pointes occurred in less than 1% (2/977) of patients who received Pazoren in the monotherapy trials. Pazoren should be used with caution in patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant pre-existing cardiac disease. When using Pazoren, baseline and periodic monitoring of ECGs and maintenance of electrolytes (e.g., calcium, magnesium, potassium) within the normal range should be performed.
Contraindications
It is contraindicated in patients with known hypersensitivity to Pazopanib or any other components of this product.